Melanoma
📧 Sign up to get email alerts when something new happens for Melanoma.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2022-08-03FDA Approved: TEMOZOLOMIDE — Supplemental Application (Accord Healthcare Inc.)
FDA approves a supplemental application for Temozolomide from Accord Healthcare Inc., a generic cancer drug.
-
CLINICAL_TRIALS trial_result · 2022-08-01Clinical Trial Update: A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) [Phase 1, Phase 2]
Phase 1/2 trial evaluating pembrolizumab in combination with trametinib and dabrafenib in advanced melanoma has completed with posted result…
-
FDA approval · 2022-07-28FDA Approved: COTELLIC — Supplemental Application (Genentech, Inc.)
FDA approved a supplemental application for COTELLIC (cobimetinib) submitted by Genentech, Inc.
-
CLINICAL_TRIALS research · 2022-07-20Clinical Trial Update: Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG [Phase 4]
Phase 4 clinical trial update investigating sentinel lymph node detection in melanoma patients using MSOT and ICG.
-
CLINICAL_TRIALS trial_result · 2022-07-14Clinical Trial Update: Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker [Phase 2]
Phase 2 trial evaluating pembrolizumab in treatment-naïve distant metastatic melanoma with use of C11-AMT PET imaging at baseline as a bioma…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2022-06-27Clinical Trial Update: Study of PI-88 in Patients With Advanced Melanoma [Phase 1, Phase 2]
Clinical trial update for PI-88 in advanced melanoma spanning Phase 1 and Phase 2, status completed.
-
CLINICAL_TRIALS trial_result · 2022-06-27Clinical Trial Update: PI-88 in Treating Patients With an Advanced Malignancy (Cancer) or Stage IV Melanoma [Phase 1, Phase 2]
A completed phase 1/2 trial evaluating PI-88 in patients with melanoma and unspecified adult solid tumors.
-
CLINICAL_TRIALS trial_result · 2022-06-24Clinical Trial Update: Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) [Phase 3]
Phase 3 trial assessing pembrolizumab versus placebo in patients with resected high-risk stage II melanoma reports safety and efficacy resul…
-
CLINICAL_TRIALS trial_result · 2022-06-14Clinical Trial Update: Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma [Phase 2]
Phase 2 trial evaluating temozolomide with sorafenib in metastatic or unresectable melanoma has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2022-06-09Clinical Trial Update: Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility Study [Phase 4]
Phase 4 clinical trial update on volatile anesthesia and perioperative outcomes in cancer patients; study completed.
-
CLINICAL_TRIALS trial_result · 2022-05-31Clinical Trial Update: Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 [Phase 1, Phase 2]
Phase 1/2 trial evaluating NY-ESO-1–targeted T-cell therapy with or without decitabine in patients with NY-ESO-1–expressing advanced cancers…
-
CLINICAL_TRIALS trial_result · 2022-05-20Clinical Trial Update: E6201 Plus Dabrafenib for the Treatment of Metastatic Melanoma Central Nervous System Metastases (CNS) [Phase 1]
Phase 1 clinical trial evaluating E6201 in combination with dabrafenib for metastatic melanoma with brain metastases; study terminated with …
-
CLINICAL_TRIALS trial_result · 2022-05-18Clinical Trial Update: Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) [Phase 1, Phase 2]
Phase 1/2 trial assessing safety and tolerability of pembrolizumab combined with pegylated interferon alfa-2b or with ipilimumab in advanced…
-
CLINICAL_TRIALS trial_result · 2022-05-16Clinical Trial Update: Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma [Phase 3]
Phase 3 trial update for pembrolizumab with talimogene laherparepvec vs placebo in unresectable melanoma has been terminated with results po…
-
CLINICAL_TRIALS trial_result · 2022-05-10Clinical Trial Update: A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) [Phase 2]
Phase 2 clinical trial update for INCMGA00012 in selected solid tumors, with completed status and results posted.
-
CLINICAL_TRIALS trial_result · 2022-05-06Clinical Trial Update: Combined Therapy of Nivolumab and Adoptive T Cell Therapy in Metastatic Melanoma Patients [Phase 1, Phase 2]
Clinical trial update on combined nivolumab and adoptive T cell therapy in metastatic melanoma across Phase 1 and Phase 2.
-
CLINICAL_TRIALS trial_result · 2022-05-03Clinical Trial Update: A Phase II Clinical Trial to Evaluate HLX208 in Advanced Melanoma Patients With BRAF V600 Mutation [Phase 2]
Phase II trial evaluating HLX208 in advanced melanoma with BRAF V600 mutation.
-
CLINICAL_TRIALS trial_result · 2022-04-21Clinical Trial Update: Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma [Phase 2]
Phase 2 trial evaluating pembrolizumab in combination with ipilimumab after prior immunotherapy in melanoma, with results posted.
-
CLINICAL_TRIALS trial_result · 2022-04-15Clinical Trial Update: Combination Therapy of F16IL2 and Paclitaxel in Solid Tumour Patients [Phase 1, Phase 2]
Phase 1/2 trial evaluating the combination of F16IL2 with paclitaxel in solid tumors, including breast cancer, completed.
-
CLINICAL_TRIALS trial_result · 2022-04-14Clinical Trial Update: A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma [Phase 1, Phase 2]
Phase I/II dose-escalation study of L19-IL2 antibody-cytokine fusion protein with dacarbazine for metastatic melanoma (Phase 1/Phase 2).
-
CLINICAL_TRIALS trial_result · 2022-04-14Clinical Trial Update: Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma [Phase 2]
Phase 2 trial update evaluating monoclonal antibody therapy and vaccine therapy in patients with resected stage III or stage IV melanoma; re…
-
CLINICAL_TRIALS trial_result · 2022-04-13Clinical Trial Update: Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma [Phase 2]
Phase 2 trial assessing denileukin diftitox in patients with Stage IIIC and Stage IV melanoma has completed with posted results.
-
CLINICAL_TRIALS trial_result · 2022-04-07Clinical Trial Update: Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma [Phase 1, Phase 2]
Clinical trial updates evaluating denosumab in combination with immune checkpoint inhibitors in unresectable or metastatic melanoma (Phase 1…
-
CLINICAL_TRIALS trial_result · 2022-03-31Clinical Trial Update: Phase Ib/II Clinical Study of Pexa-Vec (Vaccinia GM CSF / Thymidine Kinase-Deactivated Virus) Combined With Recombinant Whole Human Anti-PD-L1 Monoclonal Antibody (ZKAB001) in Metastatic Melanoma [Phase 1, Phase 2]
Phase Ib/II clinical study evaluating Pexa-Vec in combination with anti-PD-L1 antibody ZKAB001 for metastatic melanoma after failed first-li…
-
CLINICAL_TRIALS trial_result · 2022-03-29Clinical Trial Update: A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma [Phase 2, Phase 3]
A Phase 2/3 trial comparing relatlimab plus nivolumab versus nivolumab alone in advanced melanoma has results posted, with the study current…